Please use this identifier to cite or link to this item:
https://dora.health.qld.gov.au/qldresearchjspui/handle/1/5648| Title: | Australia and New Zealand Transplant and Cellular Therapies (ANZTCT) position statement: COVID‐19 management in patients with haemopoietic stem cell transplant and chimeric antigen receptor T cell | Authors: | Perram, Jacinta Purtill, Duncan Bajel, Ashish Butler, Jason O'Brien, Tracey Teh, Benjamin Gilroy, Nicole Ho, Phoebe J. Doocey, Richard Hills, Thomas Perera, Travis Douglas, Genevieve Ramachandran, Shanti Chee, Lynette Trotman, Judith Weinkove, Robert Keogh, Steven Fraser, Chris Cochrane, Tara Watson, Anne‐Marie |
Issue Date: | 2023 | Source: | Internal Medicine Journal, 2023 (53) 1 p.119-125 | Pages: | 119-125 | Journal Title: | Internal Medicine Journal | Abstract: | Patients with post‐haemopoietic stem cell transplant or chimeric antigen receptor T ‐cell (CAR‐T) therapy face a significant risk of morbidity and mortality from coronavirus disease 2019 because of their immunosuppressed state. As case numbers in Australia and New Zealand continue to rise, guidance on management in this high‐risk population is needed. Whilst we have learned much from international colleagues who faced high infection rates early in the pandemic, guidance relevant to local health system structures, medication availability and emerging therapies is essential to equip physicians to manage our patients optimally. | DOI: | 10.1111/imj.15978 | Resources: | https://search.ebscohost.com/login.aspx?direct=true&AuthType=ip,athens&db=ccm&AN=161474016&site=ehost-live |
| Appears in Sites: | Children's Health Queensland Publications |
Show full item record
Items in DORA are protected by copyright, with all rights reserved, unless otherwise indicated.